Customize View
Named by Company
Named by Competitor
Named by Third Party

Recently disclosed competitors only (within the last two years)
Include Competitors for:Current subsidiaries


Competitors

Recently Disclosed Competitors
Competitor's Name
LTM Revenue ($mm)
LTM Date
Source
Adare Pharmaceuticals, Inc.
-
-
Societal CDMO, Inc. (NasdaqCM:SCTL) 2023 Form 10-K
Business Description: Adare Pharmaceuticals, Inc., a contract development, and manufacturing organization, develops, manufactures, and markets pharmaceutical technologies for customers worldwide. The company offers patient-centric solutions, such as taste-masked products and alternative dosage forms; a customized drug release platform, which releases drug profiles tailored to therapeutic performance; and a bioavailability enhancement platform that improves solubility within the gastrointestinal tract. In addition, it also develops and provides Stratµm, a microencapsulation technology; Optimμm, an oral dose microcapsules; Unisun, for intratympanic delivery; and Advatab for oral disintegration. Adare Pharmaceuticals, Inc. was formerly known as Aptalis Pharmatech, Inc. The company was incorporated in 2015 and is based in Lawrenceville, New Jersey. It has a manufacturing and formulation, and research and development facility in Vandalia, Ohio. It has manufacturing facilities in Canada, Italy, and France. Adare Pharmaceuticals, Inc. is a former subsidiary of Allergan plc.
Aenova Group GmbH
-
-
Procaps Group S.A. (NasdaqGM:PROC) 2023 Form 20-F
Business Description: Aenova Group GmbH develops, manufactures, and markets solid, semi-solid, and liquid pharmaceutical products for the healthcare industry worldwide. The company develops and manufactures generics, OTC products, and dietary supplements. Its service portfolio includes development, production, packaging, supply chain management, analytics, and service and support for various dosage forms, including soft and hard capsules, tablets, film-coated tablets, liquids, ointments, creams, gels, granules, pellets, and effervescent products. Aenova Group GmbH was formerly known as Dragenopharm Apotheker Püschl GmbH & Co. Kg and changed its name to Aenova Group GmbH in 2008. The company was founded in 1949 and is based in Starnberg, Germany. It has production sites in Pähl, Tittmoning, Bad Aibling, Feldkirchen/Bruckmühl, Munich, and Marburg, Germany; Lyon, France; Killorglin, Ireland; Sisseln, Kirchberg, and Muttenz, Switzerland; Cornu, Romania; Carugate, Italy; and Miami, Florida.
Allergan plc
16,096.20
Mar-31-2020
Catalent Pharma Solutions, Inc. 2013 Form 10-K
Business Description: Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, central nervous system, women’s health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; In addition, it develops medical and cosmetic treatments; treatments for neurodegenerative disorders; and inflammatory and fibrotic diseases. It has a collaboration, option, and license agreement with Lyndra, Inc. to develop orally administered products for the treatment of Alzheimer’s disease; strategic alliance and option agreement with Editas Medicine, Inc.; and Allergan plc also has licensing agreements with Assembly Biosciences, Inc. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was incorporated in 2013 and is headquartered in Dublin, Ireland. As of May 8, 2020, Allergan plc operates as a subsidiary of AbbVie Inc.
Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821)
1,341.67
Jun-30-2023
Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) - Form Doc
Business Description: Asymchem Laboratories (Tianjin) Co., Ltd. engages in the provision of contract development and manufacturing services focuses on innovation and commercial application of global pharmaceutical technology in Mainland China and internationally. The company offers research and development, and production services for pharmaceutical and biotech companies. Its solutions range from early clinical stage to commercial stage, including research and development, and cGMP production of advanced intermediates, active pharmaceutical ingredients, and formulations, as well as clinical research services. The company also engages in the provision of pharmaceutical analysis and testing services; information technology services; and pharmaceutical science and technology development activities, as well as sale, wholesale, and retail of drugs. In addition, it is involved in the manufacture, development, and sale of medicine raw materials and relevant products; manufacture of chemical products; and technology development activities. The company was founded in 1999 and is headquartered in Tianjin, China.
Avara Pharmaceutical Services, Inc.
35.38
-
Societal CDMO, Inc. (NasdaqCM:SCTL) 2023 Form 10-K
Business Description: Avara Pharmaceutical Services, Inc. provides contract manufacturing and technical services to the biopharmaceutical market worldwide. The company offers bulk drug formulation and manufacturing, including granulation, coating, blending, encapsulation, compression, and drying tablets and capsules. It also provides primary and secondary packaging capabilities for solid dose drugs. The company was incorporated in 2015 and is headquartered in Norwalk, Connecticut.
BioDuro-Sundia
53.39
-
Societal CDMO, Inc. (NasdaqCM:SCTL) 2022 Form 10-K
Business Description: BioDuro-Sundia, a life sciences research organization, provides drug discovery services for life science, biotechnology, and pharmaceutical industries worldwide. The company offers services in the areas of chemistry, discovery biology, drug metabolism and pharmacokinetics, and pharmacology, as well as integrated preclinical research and development. It also provides hTME-3DX Screen and Verify, a platform for humanized tumor microenvironment, three-dimensional drug screening, and patient-derived xenograft verification. BioDuro-Sundia was formerly known as BioDuro, LLC and changed its name to BioDuro-Sundia in September 2020. The company was incorporated in 2005 and is based in Irvine, California.
Bioserv Corporation
0.84
-
Societal CDMO, Inc. (NasdaqCM:SCTL) 2022 Form 10-K
Business Description: Bioserv Corporation doing business as NextPharma Technologies operates as a contract manufacturing organization. It provides pharmaceutical services, including bulk formulation/compounding, custom formulation, sterile filtration and filter integrity testing, aseptic liquid and powder filling, aseptic lyophilization, visual inspection, custom label printing and application, custom packaging and kitting, CGMP batch record documentation, and controlled temperature storage services. The company also offers medical device/diagnostic services, such as clarifying or sterile filtration, liquid or powder filling, custom lyophilization, diagnostic test kit production and assembly, and electronic and medical device assembly services. It serves biotechnology, pharmaceutical, diagnostic, medical device, and cosmetic industries in the United States and internationally. The company was founded in 1988 and is based in San Diego, California. As per the transaction announced on June 27, 2007, Bioserv Corporation operates as a subsidiary of Sorrento Therapeutics, Inc.
Cambrex Corporation
618.06
Sep-30-2019
Dr. Reddy's Laboratories Limited (BSE:500124) 2023 Form 20-F
Business Description: Cambrex Corporation operates as a life sciences company that provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company caters to generic drug companies and companies that discover and commercialise small-molecule human therapeutics. The company sells its products directly as well as through independent agents. Cambrex Corporation was founded in 1981 and is based in East Rutherford, New Jersey with an additional office in Charles, Iowa.
Cardinal Health, Inc. (NYSE:CAH)
205,012.00
Jun-30-2023
Dr. Reddy's Laboratories Limited (BSE:500124) 2016 Form 20-F
Business Description: Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Catalent, Inc. (NYSE:CTLT)
4,276.00
Jun-30-2023
Dr. Reddy's Laboratories Limited (BSE:500124) 2023 Form 20-F
Business Description: Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Corden Pharma GmbH
21.41
-
Societal CDMO, Inc. (NasdaqCM:SCTL) 2023 Form 10-K
Business Description: Corden Pharma GmbH provides contract development and manufacturing services of APIs, drug products, and associated packaging services to pharmaceutical and biotechnology companies. The company specializes in route scouting and process development for proprietary and generic APIs; synthetic peptide API production; high potency solid dosage forms; oral and sterile oncology drug products; proprietary and generic API and drug product manufacturing; formulation, and primary and secondary packaging; and clinical trial and pharma logistics services. It offers API development and contract manufacturing, generic API manufacturing, highly potent APIs, sterile APIs, peptides, building blocks, conjugate products, carbohydrates, derivatized phospholipids, and support services; and drug product development and contract manufacturing, sterile formulation, highly potent formulation oncology, cephalosporin manufacturing, penicillin manufacturing, parenterals, large pre-filled syringes, sterile oncology, oral oncology, two-layer tablets, clinical supply, packaging, pharma-logistics, and support services. CordenPharma International has a strategic collaboration with GE Healthcare. The company was founded in 1970 and is based in Plankstadt, Germany. It has facilities in Bergamo, Caponago, and Sermoneta, Italy; Boulder, Colorado; Brussels, Belgium; Chenôve, France; Plankstadt and Frankfurt, Germany; and Liestal, Switzerland. As of February 1, 2008, Corden Pharma GmbH operates as a subsidiary of International Chemical Investors S.E.
CoreRx, Inc.
66.97
-
Societal CDMO, Inc. (NasdaqCM:SCTL) 2023 Form 10-K
Business Description: CoreRx, Inc. operates as a contract development manufacturing organization (CDMO) with a focus on clinical phase drug product development for pharmaceutical and biotechnology companies in the United States and internationally. The company provides services for the development, manufacturing, and testing of solid, liquid, and semi-solid dosage forms. The company offers pre-formulation services, such as physical and chemical characterization, pH/solubility profile, partition coefficient, thermal analysis, hygroscopicity evaluation, and chemical and physical stability evaluations; formulation and development services for tablets and other dosage forms; stability indicating assay and related substances methods, including blend uniformity and content uniformity evaluation; manufacturing and packaging of various medication forms, such as tablets, capsules, coating, liquid oral dosage forms, gels, creams, ointments, lotions, and powder; analytical and stability; pediatric expertise; and bioavailability. The company was incorporated in 2006 and is based in Clearwater, Florida with an additional office in San Rafael, California.
Curia Global, Inc.
680.82
Jun-30-2017
Dr. Reddy's Laboratories Limited (BSE:500124) 2023 Form 20-F
Business Description: Curia Global, Inc. operates as a contract research, development, and manufacturing organization. The company discovers and develops an active pharmaceutical ingredient (API); and develops a messenger RNA (mRNA) solution to streamline the development and delivery of mRNA-based products. It offers custom API manufacturing, fermentation, finished dosage form, high potency, lipid nanoparticle, rare/orphan, stability and release testing, sterile fill finish, APIs and intermediates catalog, and fine chemicals catalog. The company offers analytical testing services, batch release and stability lot testing, extractables and leachable, method development and validation, package and device testing, and solid-state chemistry lab testing services. It also offers intellectual property litigation support, intellectual property services, regulatory support, quality assurance, and sterile university consultative services. The company offers products and services from research and development through commercial manufacturing to pharmaceutical and biopharmaceutical customers. The company was formerly known as AMRI and changed its name to Curia Global, Inc. in July 2021. Curia Global, Inc. was founded in 1991 and is headquartered in Albany, New York.
Dr. Reddy's Laboratories Limited (BSE:500124)
3,135.23
Jun-30-2023
Dr. Reddy's Laboratories Limited (BSE:500124) 2023 Form 20-F
Business Description: Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
DSM-Firmenich AG (ENXTAM:DSFIR)
9,255.93
Jun-30-2023
Dr. Reddy's Laboratories Limited (BSE:500124) 2016 Form 20-F
Business Description: DSM-Firmenich AG, a science-based company, engages in beauty, health, and nutrition businesses in the Netherlands, Switzerland, rest of Europe, North America, Latin America, China, rest of Asia, and internationally. It operates through Perfumery & Beauty; Animal Nutrition & Health (ANH); Health, Nutrition & Care (HNC); and Food & Beverage segments. The Perfumery & Beauty offers perfumery and aroma ingredients. The Animal Nutrition & Health segment offers essential products, including vitamins, premixes, and carotenoids; performance solutions, such as enzymes, microbes, and eubiotics; precision services comprising support with data analysis to measure animal health and environmental footprint on farm level and feed safety; and methane reducing feed additive for ruminants. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, personal care and aroma, and biomedical materials markets. It offers vitamins, nutritional lipids, minerals, carotenoids, nutraceuticals, digestive enzymes, probiotics and prebiotics, active pharmaceutical ingredients, and sunscreen filters, as well as a range of biomedical solutions; premix, market-ready solutions, and personalized nutrition solutions; and regulatory affairs and formulation expertise, and customized solutions. The Food & Beverage segment provides ingredients and solutions for use in a range of food products, such as dairy; bakery, cereals, and bars; savory food; beverages and brewing; confectionery and fruit; plant-based meat and fish alternatives; and petfood. The company was founded in 1902 and is headquartered in Kaiseraugst, Switzerland.
Eurofins Scientific SE (ENXTPA:ERF)
6,857.79
Jun-30-2023
Eurofins Scientific SE (ENXTPA:ERF) - Form Doc
Business Description: Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 130,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; and testing for persistent organic pollutants, dioxins and organic contaminants, pesticides, mycotoxins, allergens, and pathogens and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
FAREVA SA
-
-
Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) - Form Doc
Business Description: FAREVA SA, a subcontractor, provides research, manufacturing, and packaging services for cosmetic, make-up, pharmaceutical, industrial, and household products. The company engages in the formulation, manufacture, and filling of active pharmaceutical ingredients, sterile and injectable products, ophthalmic solutions, food supplements, and conventional products; body care and hygiene products, hair and facial care products, products for men, styling products, face cleansers, and oral hygiene products; makeup products; and household cleaners, leather and textile care products, room fragrances, pet care products, insecticides, industrial and car maintenance products, and paints and varnishes. FAREVA SA was founded in 1981 and is based in Luxembourg, Luxembourg. It has locations in France, Europe, and internationally.
Frontage Laboratories, Inc.
198.78
-
Societal CDMO, Inc. (NasdaqCM:SCTL) 2022 Form 10-K
Business Description: Frontage Laboratories, Inc. operates as a contract research organization that provides scientific and analytical services to pharmaceutical and biotech companies worldwide. The company offers drug metabolism and pharmacokinetics services, such as drug discovery and development, in vitro studies, in vivo studies, and radio and stable isotope-labeled studies; agrochemical services, including Non-GLP and GLP/EPA-compliant quantitative analyses, radio-labeled studies, and synthesis of potential metabolites; and small molecule bioanalytical development services, which include method development and validation, clinical biomarker and immunogenicity, biomarker assay development and validation, streamlined sample management and processing, and scientific and regulatory affairs consultant. The company also provides chemistry, manufacturing, and control (CMC) product development services that comprise organic synthesis, pharmaceutical formulation development, good manufacturing practices (GMP) analytical testing, and GMP clinical trial material manufacturing for various drug candidates ranging from novel early phase projects to generic-equivalent and consumer care medications; and CMC analytical, large molecule bioanalytical development, clinical research, and GMP consulting services. Frontage Laboratories, Inc. was founded in 2001 and is based in Exton, Pennsylvania with a branch office in Princeton, New Jersey. It also has pharma research and development sites in Exton, Pennsylvania; Hackensack and Secaucus, New Jersey; and Shanghai and Suzhou, China. Frontage Laboratories, Inc. operates as a subsidiary of Frontage Holdings Corporation.
Lonza Group AG (SWX:LONN)
7,031.03
Jun-30-2023
Dr. Reddy's Laboratories Limited (BSE:500124) 2023 Form 20-F
Business Description: Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was incorporated in 1897 and is headquartered in Basel, Switzerland.
Metrics, Inc.
49.62
-
Societal CDMO, Inc. (NasdaqCM:SCTL) 2022 Form 10-K
Business Description: Metrics, Inc. provides contract services for the development and manufacture of pharmaceutical drugs. It offers formulation research and development services for oral and topical dosage forms; proprietary pellet technologies that enable controlled release of active pharmaceutical ingredients; pharmaceutical development services for drug product formulation development, fast track to clinical trials, and potent products; and taste masking for liquids and tablets. The company also provides analytical testing services for methods development and validation, stability studies, raw materials, trace metals, and microbiology; and clinical trial and commercial manufacturing services. Metrics, Inc. was founded in 1994 and is based in Greenville, North Carolina. Metrics, Inc. operates as a subsidiary of Mayne Pharma (USA), Inc. As of October 3, 2022, Metrics, Inc. operates as a subsidiary of Catalent, Inc.
Mikart, LLC
35.25
-
Societal CDMO, Inc. (NasdaqCM:SCTL) 2020 Form 10-K
Business Description: Mikart, LLC provides product development, contract manufacturing, and packaging services to the pharmaceutical industry. The company specializes in a range of drug compounds, including controlled drug substances. Its product development services include pre-formulation, formulation development, method development, process optimization, scale-up, site/tech transfers, and product application support; and packaging services comprise bottle filling, blister packaging, pouch/foil strip packaging, and cartoning/tray packaging. The company offers contract manufacturing services for products in the form of tablets, capsules, soft gels, non-sterile liquids, and powders/granules; and manufactures and packages controlled drug substances, as well as clinical trials, supplies for solid oral dose and non-sterile liquid products controlled substances. Mikart, LLC was founded in 1975 and is based in Atlanta, Georgia.
Perrigo Company plc (NYSE:PRGO)
4,630.20
Jul-01-2023
Catalent Pharma Solutions, Inc. 2013 Form 10-K
Business Description: Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in Ireland, the United States, France, Belgium, China, the United Kingdom, Germany, Switzerland, Austria, Italy, Australia, Greece, and Spain. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment develops, manufacture, and markets self-care products including upper respiratory, pain and sleep-aids, digestive health, nutrition, healthy lifestyle, skincare, women’s health, and other products, as well as vitamins, minerals and supplements, and oral self-care in the United States and Canada. This segment offers its products under Burt's Bees, Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, and Steripod brands. Consumer Self-Care International segment comprises consumer self-care product categories outside the U.S. and Canada, including branded products in Europe and Australia, and store brand products in the United Kingdom and parts of Europe and Asia, which develops, manufactures, markets, and distributes consumer self-care brands through a network of drug and grocery store retailers, e-commerce stores, and para-pharmacies in more than 29 countries, primarily in Europe. In addition, the company offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Pharmaceutics International, Inc.
36.00
-
Societal CDMO, Inc. (NasdaqCM:SCTL) 2023 Form 10-K
Business Description: Pharmaceutics International, Inc. operates as a science-driven contract development and manufacturing company. It offers dosage form development and cGMP manufacturing services to biotech and specialty pharmaceutical industries. It manufactures a range of dosage forms, such as conventional tablets and capsules; controlled/delayed-release tablets and capsules; hard gelatin/HPMC liquid-filled capsules; soft gels; hot-melt extrusion; spray drying; powder for reconstitution; amorphous solid solutions; liquid formulations; inhalations (DPI, MDI, and nasal sprays); micronization/nanoparticle/microfluidization products; ointments/creams/gels; suspensions/syrups/solutions; sterile injectable products; freeze-dried products; and coated beads, tablets, and capsules. The company offers pre-formulation, formulation, clinical trial materials manufacturing, commercial manufacturing, clinical packaging and labeling, and clinical trial kit building and distribution services. Pharmaceutics International, Inc. was founded in 1994 and is based in Hunt Valley, Maryland.
Pharmaron Beijing Co., Ltd. (SZSE:300759)
1,541.53
Jun-30-2023
Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) - Form Doc
Business Description: Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, rest of Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Preparation Process Development, and Production Services; Clinical Research Services; Macromolecule and Cell, and Gene Therapy Services; and Others. The company offers laboratory chemical services, including medicinal chemistry, synthetic chemistry, analytical and purification chemistry, and computer-aided drug design; bioscience services, such as in vitro and in vivo drug metabolism and pharmacokinetics, in vitro biology and in vivo pharmacology, drug safety evaluation, and US laboratory services; and process development and production, material science/preparation, preparation development and production, and analytical development services. It also provides radiolabeling science and early clinical trial services; clinical trial and clinical research site management services; and macromolecular drug discovery and development, and production services (CDMO), as well as cell and gene therapy laboratory, and gene therapy CDMO services. In addition, the company provides safety assessment, and chemistry, manufacturing, and controls services. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Porton Pharma Solutions Ltd. (SZSE:300363)
746.64
Jun-30-2023
Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) - Form Doc
Business Description: Porton Pharma Solutions Ltd. manufactures and supplies small molecule active pharmaceutical ingredients and drug intermediates, dosage forms, and biologics to the pharmaceutical companies. The company was formerly known as Porton Fine Chemicals Ltd. and changed its name to Porton Pharma Solutions Ltd. in January 2018. Porton Pharma Solutions Ltd. was founded in 2005 and is headquartered in Chongqing, China.
Procaps Group S.A. (NasdaqGM:PROC)
406.09
Jun-30-2023
Procaps Group S.A. (NasdaqGM:PROC) 2023 Form 20-F
Business Description: Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
Quotient Sciences Limited
94.15
-
Societal CDMO, Inc. (NasdaqCM:SCTL) 2023 Form 10-K
Business Description: Quotient Sciences Limited, a drug development and manufacturing accelerator, provides integrated programs and tailored services to pharmaceutical and biotechnology customers worldwide. The company offers candidate selection, early development, and late development integrated programs. It also offers formulation development, clinical trial manufacturing, commercial manufacturing, clinical pharmacology, drug development consulting, data sciences, drug substance, and bioanalysis services. Quotient Sciences Limited was formerly known as Quotient Clinical Ltd. and changed its name to Quotient Sciences Limited in November 2017. The company was founded in 2004 and is based in Nottingham, United Kingdom.
Recipharm AB (publ)
1,019.21
Dec-31-2020
Societal CDMO, Inc. (NasdaqCM:SCTL) 2023 Form 10-K
Business Description: Recipharm AB (publ) operates as a pharmaceutical contract development and manufacturing company in Sweden, the United Kingdom, Italy, Germany, France, India, Spain, Portugal, and internationally. It operates through four segments: Advanced Delivery Systems (ADS), Manufacturing Steriles (MFG-S), Manufacturing Solids & Others (MFG-SO), and Development & Licensing (D&L). The ADS segment develops and manufactures inhalation products and devices, including integrated drug solutions, medical check valves, and injection devices. The MFG-S segment manufactures sterile products using lyophilisation and blow-fillseal technologies. The MFG-SO segment manufactures non-sterile products, such as tablets, capsules, semi-solids, liquids, and powders. The D&L segment provides pharmaceutical development services, including preclinical and formulation development, and clinical trial material services; manages patents, technologies, and drug product rights; and develops and manufactures drug substance. It also offers packaging products comprising bottles, blisters, stick-packs, vials, ampoules, syringes, pouches, and patches; and online vendor managed inventory solutions. The company was founded in 1994 and is headquartered in Stockholm, Sweden.
Samsung Biologics Co.,Ltd. (KOSE:A207940)
2,530.75
Jun-30-2023
WuXi Biologics (Cayman) Inc. (SEHK:2269) - Form Doc
Business Description: Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Shanghai SynTheAll Pharmaceutical Co., Ltd.
402.31
Mar-31-2019
Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) - Form Doc
Business Description: Shanghai SynTheAll Pharmaceutical Co., Ltd. provides services for the development and manufacture of active pharmaceutical ingredients (API). Its services range from preclinical to commercial development and manufacturing services for small molecule API and advanced intermediates to the life sciences community worldwide. The company offers services, such as early stage process development, such as synthetic route and process development; late stage process development, including commercial route development, commercial process development and optimization, and process validation/DOE/QbD; R&D manufacturing, such as pre-clinical and clinical batches manufacturing; and commercial manufacturing, including registration and commercial supplies. It also provides process analytical science services, such as analytical method development and validation; characterization, in process control, and release testing; impurity structure elucidation; and ICH stability studies. In addition, the company offers process engineering services, including crystallization process development, polymorph and salt screening, solid state characterization, process scale up, particle size control, and process safety evaluation; and project management services. Shanghai SynTheAll Pharmaceutical Co., Ltd. has a strategic partnership with Antengene Corporation. The company was founded in 2003 and is headquartered in Shanghai, China. Shanghai SynTheAll Pharmaceutical Co., Ltd. operates as a subsidiary of WuXi AppTec Co., Ltd.
Societal CDMO, Inc. (NasdaqCM:SCTL)
89.19
Jun-30-2023
Societal CDMO, Inc. (NasdaqCM:SCTL) 2023 Form 10-K
Business Description: Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecules in the United States and internationally. It provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
Viatris Inc. (NasdaqGS:VTRS)
15,601.90
Jun-30-2023
Societal CDMO, Inc. (NasdaqCM:SCTL) 2020 Form 10-K
Business Description: Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
WuXi AppTec Co., Ltd. (SHSE:603259)
5,534.64
Jun-30-2023
Dr. Reddy's Laboratories Limited (BSE:500124) 2023 Form 20-F
Business Description: WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People’s Republic of China, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical testing services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People’s Republic of China.
WuXi Biologics (Cayman) Inc. (SEHK:2269)
2,263.96
Jun-30-2023
WuXi Biologics (Cayman) Inc. (SEHK:2269) - Form Doc
Business Description: WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development, and manufacturing in the People’s Republic of China, North America, Europe, and internationally. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and material supplier activities. The company was incorporated in 2014 and is headquartered in Wuxi, China.
WuXi PharmaTech (Cayman) Inc.
778.47
Sep-30-2015
Dr. Reddy's Laboratories Limited (BSE:500124) 2022 Form 20-F
Business Description: Wuxi PharmaTech (Cayman) Inc. operates as a pharmaceutical, biotechnology, and medical device research and development services company in China and the United States. It operates through two segments, Laboratory Services and Manufacturing Services. The Laboratory Services segment offers services for small molecules, such as synthetic chemistry, biology, medicinal chemistry, DMPK/ADME, formulation, analytical chemistry, toxicology, clinical development, bioanalytical, genomics, bioinformatics, research reagent production, and clinical services; services for discovery and development of biologics; and laboratory services, including testing services for biologics, medical devices, and combination products, as well as production of cell therapies. The Manufacturing Services segment provides manufacturing services, including development of manufacturing processes; and the production of advanced intermediates and active pharmaceutical ingredients for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products, and in commercial products, as well as the production of biologic products. The company sells its products to pharmaceutical, biotechnology, and medical device companies, as well as academic institutions and non-profit organizations. Wuxi PharmaTech (Cayman) Inc. has a strategic partnership with Gilead Sciences Inc. to conduct analytical and stability studies of small-molecule new chemical entities; and strategic collaboration with Eli Lilly and Company to develop, manufacture, and commercialize a novel small molecule. Wuxi PharmaTech (Cayman) Inc. was founded in 2000 and is headquartered in Shanghai, China. As of December 10, 2015, WuXi PharmaTech (Cayman) Inc. was taken private. Wuxi PharmaTech (Cayman) Inc. operates as a subsidiary of New WuXi Life Science Limited.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456)
785.72
Jun-30-2023
Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) - Form Doc
Business Description: Zhejiang Jiuzhou Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients (API) and intermediates in China and internationally. Its API pipeline comprise central nervous system, non-steroidal, anti-infection, hypoglycemic and antiviral, tumor treatment, anti-depressant, Parkinson, HCV drugs, diabetes, cardiovascular, and respiratory anti-infection drugs. The company also provides asymmetric catalysts and lithium battery materials. Zhejiang Jiuzhou Pharmaceutical Co., Ltd was founded in 1973 and is headquartered in Taizhou, China.
*denotes proprietary relationship